SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-5.72%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$885M
AUM Growth
+$885M
(-11%)
Cap. Flow
-$6.29M
Cap. Flow
% of AUM
-0.71%
Top 10 Holdings %
Top 10 Hldgs %
99.96%
Holding
11
New
–
Increased
–
Reduced
2
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
Gilead Sciences
GILD
|
$4.24M |
| 2 |
Mersana Therapeutics
MRSN
|
$2.04M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alkermes
ALKS
$4.78B
| $314M | 35.43% | 14,040,000 | – | – |
|
2
Biogen
BIIB
$19.4B
| $172M | 19.4% | 643,000 | – | – |
|
3
Ironwood Pharmaceuticals
IRWD
$214M
| $170M | 19.19% | 16,390,000 | – | – |
|
|
4
Gilead Sciences
GILD
$140B
| $78.5M | 8.88% | 1,273,100 -68,800 | -5% | -$4.24M |
|
5
Innoviva
INVA
$1.29B
| $76.8M | 8.68% | 6,614,000 | – | – |
|
|
6
Mersana Therapeutics
MRSN
$36.5M
| $27M | 3.05% | 3,997,010 -302,287 | -7% | -$2.04M |
|
|
AMRN
7
Amarin Corp
AMRN
$311M
| $26.2M | 2.96% | 23,998,000 | – | – |
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| $17.5M | 1.98% | 1,390,790 | – | – |
|
9
Vor Biopharma
VOR
$250M
| $2.46M | 0.28% | 618,000 | – | – |
|
|
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $1.02M | 0.12% | 500,356 | – | – |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $315K | 0.04% | 185,183 | – | – |
|